Congress and regulating agencies including the FTC and HHS scrutinized PBM business practices and ... down 32.2% from its 2022 performance due to biosimilar competition. One might expect that ...
“From our inception, we always believed that a transparent approach where we were paid to administer and then had some compensation transparently based on performance was a better approach.
About Psyence Biomed Psyence Biomedical Ltd. (Nasdaq: PBM) is the world’s first life science biotechnology ... There are numerous risks and uncertainties that may cause actual results or performance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback